Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PG-011 gel in prurigo nodularis
CTR20212764Phase 2Completed
- Sponsor
- 普祺医药
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pumecitinib in prurigo nodularis (PN), chronic pruritus (CP), sponsored by 普祺医药. Started Oct 2021; status: completed.
02
Drugs
pumecitinib
03
Conditions
prurigo nodularis (PN)chronic pruritus (CP)
Beyond the preview
Go deeper on CTR20212764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212764.